Corvus Pharmaceuticals
CRVS
47 hedge funds and large institutions have $31.9M invested in Corvus Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 8 closing their positions.
8% more call options, than puts
Call options by funds: $79K | Put options by funds: $73K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 48 → 47 (-1)
2.62% less ownership
Funds ownership: 39.12% → 36.5% (-2.6%)
6% less capital invested
Capital invested by funds: $33.8M → $31.9M (-$1.9M)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$298K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$157K |
| 3 |
JP Morgan Chase
New York
|
+$109K |
| 4 |
Renaissance Technologies
New York
|
+$104K |
| 5 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$46.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$2.11M |
| 2 |
SC
Samlyn Capital
New York
|
-$309K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$241K |
| 4 |
Two Sigma Investments
New York
|
-$163K |
| 5 |
MA
MYDA Advisors
Woodmere,
New York
|
-$125K |
CRVS Hedge Fund Activity: Q1 2024 in Review
47 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2024, worth a combined $31.9M — down 5.6% from $33.8M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CRVS and 7 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $298K. The largest seller was BVF Inc, cutting an estimated $2.11M.
- 47 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2024, down from 48 in Q4 2023.
- Funds reported $31.9M of Corvus Pharmaceuticals stock for Q1 2024, down 5.6% quarter-over-quarter.
- 7 funds opened new Corvus Pharmaceuticals positions in Q1 2024 and 8 closed out, a net change of -1 holder.
- The largest Corvus Pharmaceuticals buyer in Q1 2024 was Vanguard Group, an estimated $298K added.
- The largest Corvus Pharmaceuticals seller in Q1 2024 was BVF Inc, an estimated $2.11M sold.
Based on aggregated 13F filings for Q1 2024.